BREAKING: J&J to Buy Heart Failure Company Abiomed for $16.6B

“The transaction broadens Johnson & Johnson MedTech’s (JJMT) position as a growing cardiovascular innovator, advancing the standard of care in one of healthcare’s largest unmet need disease states: heart failure and recovery.”